Can I Take Omega-3 (EPA/DHA) with Synthroid (Levothyroxine)?

Levothyroxine (brand name Synthroid, also sold as generic levothyroxine sodium and under names like Levoxyl or Tirosint) is a synthetic thyroid hormone used to treat hypothyroidism and, at higher suppressive doses, to manage differentiated thyroid cancer. Omega-3 fatty acids refers here to EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid), whether from over-the-counter fish oil or krill oil, or from prescription formulations such as icosapentaenoic acid (Vascepa) or EPA+DHA ethyl esters (Lovaza).

The thesis of this page: the real question for most patients is not whether omega-3s and levothyroxine interact in the gut, because they do not, but whether the dose of omega-3 crosses a threshold where its pharmacodynamic (antiplatelet, lipid-shifting) effects start to matter for a specific patient's other medications and thyroid status. Treating "fish oil and Synthroid" as a single yes/no interaction question misses the dose- and context-dependent nuance that actually drives clinical decisions.

The direct answer, with its boundary

Omega-3 fatty acids from fish oil, krill oil, or algae-based supplements have no documented pharmacokinetic interaction with levothyroxine; they are not divalent cations and are not known to bind or displace the drug in the gastrointestinal tract the way calcium, iron, or soy can. Where caution is warranted is dose-dependent: EPA and DHA have a known antiplatelet mechanism (competing with arachidonic acid in thromboxane synthesis) that becomes clinically relevant mainly at higher intakes, and this overlaps with a separate, well-described phenomenon in which over-replacement with levothyroxine (a suppressed TSH) can itself potentiate warfarin's anticoagulant effect. Neither of these facts has been formally tested as a combined three-way interaction in a published trial, so the guidance below is built from the individual pharmacology of each agent rather than from a specific levothyroxine-omega-3 interaction study.

Why absorption is not the mechanism to worry about

Levothyroxine is absorbed mainly in the small intestine, and its absorption is meaningfully reduced by divalent and trivalent cations, such as calcium carbonate or ferrous sulfate, as well as by soy protein, bran fiber, and certain acid-reducing medications. Omega-3 fatty acids do not share that chemistry. They are lipids, not minerals, and there is no described mechanism by which fish oil or krill oil would form an insoluble complex with levothyroxine or otherwise block its uptake. This is a pharmacologic reasoning point rather than a claim backed by a dedicated levothyroxine-omega-3 absorption study, and if a reader wants a trial-level answer on this specific pairing, that trial does not appear to exist in the public literature reviewed for this article.

Where the pharmacodynamic overlap actually lives

Two separate, better-established facts combine to create the real caution zone:

Omega-3s and platelets. At higher intakes, EPA and DHA reduce platelet aggregation by competing with arachidonic acid for cyclooxygenase and thromboxane A2 production. This effect is described in the cardiovascular and lipid literature mainly in the context of prescription-dose omega-3 therapy (around 4 g/day of EPA, DHA, or both), not typical one-capsule over-the-counter dosing of 300 to 1,000 mg per day.

Levothyroxine over-replacement and anticoagulation. Hyperthyroidism, whether from disease or from a levothyroxine dose that is too high, is described in clinical reviews as a state that can increase sensitivity to warfarin by accelerating the breakdown of vitamin K-dependent clotting factors. This is a levothyroxine-warfarin interaction, not an omega-3 interaction, but it matters here because a patient on a TSH-suppressive dose (common in thyroid cancer management) who also starts prescription omega-3 therapy is layering two separate bleeding-risk-increasing mechanisms.

Neither of these facts, on its own, tells you what happens when all three factors (suppressive levothyroxine dosing, high-dose omega-3, and an anticoagulant) are present at once in the same patient. That specific three-way scenario has not been directly studied as far as this review could determine, and a pharmacist or prescriber should be consulted rather than assuming the individual risks simply add in a predictable way.

Does fish oil change TSH or thyroid lab values?

No controlled human trial reviewed for this article demonstrates that EPA or DHA supplementation directly alters TSH, free T4, or free T3. The hypothalamic-pituitary-thyroid feedback loop that governs TSH secretion has no established direct omega-3 receptor pathway.

Older rodent studies have reported that very high experimental fish-oil intakes can alter thyroid hormone transport proteins, and separate agricultural research (for example, a 2016 study examining a feed additive's effect on thyroid hormones in broiler chickens) has looked at thyroid hormone changes in non-human, non-clinical contexts Effect of KiFAY on performance, IGF-1, and thyroid hormones in broilers, 2016. Findings in poultry fed an experimental additive are not translatable to human dosing of over-the-counter fish oil, and this example is included mainly to illustrate why animal and non-mammalian data cannot substitute for human trial evidence on this question.

Biotin is the more plausible explanation for an unexpected TSH change

If a patient sees an unexpected shift in TSH while taking a fish-oil or multivitamin product, biotin is a more likely explanation than the omega-3 content itself, because many fish-oil and multivitamin blends are co-formulated with biotin. Regulatory safety communications have warned that biotin taken above roughly 5 mg/day can interfere with common immunoassay-based thyroid tests, falsely lowering measured TSH and falsely raising measured free T4 (guidance first issued in 2017 and updated in 2019; readers should check current regulatory sources for the latest status). Anyone on levothyroxine who takes a biotin-containing product should check the label and consider stopping it at least a few days before a scheduled thyroid panel, in coordination with the ordering clinician.

Hypothyroidism, lipids, and where omega-3 therapy fits

Untreated or under-treated hypothyroidism is well recognized clinically to raise LDL cholesterol and triglycerides and to lower HDL. Once levothyroxine restores TSH to target range, lipid abnormalities frequently improve on their own, which is why most guidelines recommend optimizing thyroid replacement before adding a separate lipid-lowering strategy.

For patients whose triglycerides remain elevated despite an adequate levothyroxine dose, omega-3 fatty acids, including prescription formulations, are a recognized adjunct to diet and, when indicated, statin therapy for hypertriglyceridemia. Large cardiovascular outcome trials of omega-3 therapy exist in the general population and in patients with elevated triglycerides, but this article does not carry forward specific effect-size numbers from those trials because the inherited source citations could not be independently verified against the correct paper. A prescriber discussing prescription-grade omega-3 therapy (such as icosapentaenoic acid) for a levothyroxine patient with residual hypertriglyceridemia should reference current cardiology and lipid guidelines directly rather than a secondary summary.

Thyroid cancer patients on suppressive dosing

Patients treated with levothyroxine for differentiated thyroid cancer are sometimes managed with an intentionally suppressed TSH, targeting levels below the normal reference range based on individualized cancer-recurrence risk. At those doses, cardiovascular effects such as atrial fibrillation risk and accelerated bone turnover become more clinically relevant, and any supplement with cardiovascular or hemostatic effects, including high-dose fish oil, deserves review by the endocrinologist managing the suppression target rather than being treated as a routine supplement decision. Individualized TSH targets in this population should come from the treating oncology or endocrinology team, not from a general reference article.

Timing: does omega-3 need to be separated from levothyroxine?

No mandatory separation window is described for omega-3 supplements the way there is for calcium, iron, magnesium, or soy-based products, which typically require about a 4-hour gap from levothyroxine dosing. Levothyroxine is generally taken on an empty stomach, 30 to 60 minutes before food, or at bedtime several hours after the last meal, specifically for absorption consistency. Omega-3 supplements are commonly taken with a meal because fat improves their absorption and reduces GI upset. In practice, these two schedules are usually separated by hours without any deliberate planning.

What matters more than separation is consistency: taking levothyroxine at roughly the same time relative to food every day supports stable absorption and a stable TSH, regardless of when omega-3s are taken.

Practical dose thresholds to bring to a conversation with your prescriber

• Around 1 g/day combined EPA+DHA (a single standard capsule): no specific precaution beyond routine supplement disclosure.
• 2 to 3 g/day: reasonable to mention at your next visit, particularly if you also take any medication that affects clotting.
• 4 g/day or a prescription omega-3 product: this is the range where the antiplatelet literature is strongest, and it should be discussed explicitly with your prescriber, especially if you are on an anticoagulant, on aspirin, or on a suppressive levothyroxine dose.

What is established, what is plausible, and what is not established

Evidence-status interaction assessment: omega-3 (EPA/DHA) and levothyroxine

What to tell your prescriber

Bring the exact product name, the EPA and DHA content per serving (not the total "fish oil" weight on the label, which includes other fats), how many capsules you take daily, and whether the product also contains biotin, calcium, or magnesium. A product labeled "2,000 mg fish oil" might contain only a few hundred milligrams of actual combined EPA+DHA; the rest is other fat from the fish oil itself.

Call your prescriber before your next scheduled visit if you notice new or unusual bruising or slow-healing cuts while on an anticoagulant, unexplained heart palpitations or tremor (possible signs of over-replacement), or a TSH result that has shifted noticeably from your prior stable value. A meaningful TSH shift warrants a dose review regardless of whether a supplement is the cause.

What actually requires separation from levothyroxine

For context, the supplements and medications with a well-documented absorption interaction requiring a roughly 4-hour separation from levothyroxine include calcium carbonate or citrate, iron (ferrous sulfate and similar), magnesium, aluminum-containing antacids, soy protein isoflavones, and high-fiber products like psyllium. Omega-3 fish oil is not on this list based on the pharmacology and literature reviewed here.

Where the uncertainty genuinely lies

This page can support the general pharmacologic reasoning that omega-3s do not chelate levothyroxine, and the general clinical recognition that high-dose omega-3 has antiplatelet effects while over-replacement with levothyroxine can potentiate warfarin. It cannot support precise numeric claims (specific percentage reductions in cardiovascular events, exact triglyceride mean differences, or a specific bleeding-time prolongation figure) because the inherited source citations for those numbers could not be verified against the correct paper and are not repeated here. Anyone making a treatment decision based on a specific trial result, such as a cardiovascular outcomes trial of prescription omega-3 therapy, should look up that trial directly rather than relying on a secondary summary.

This article does not provide individualized dosing advice. Levothyroxine dosing and TSH targets, and any decision to start prescription-grade omega-3 therapy, should be set by the clinician managing your thyroid condition and any cardiovascular risk factors, with input from a pharmacist if you take an anticoagulant or antiplatelet medication.